CABOTEGRAVIR AND RILPIVIRINE

Other

Oral

12.1 Mechanism of Action CABENUVA contains 2 long-acting HIV-1 antiretroviral drugs, cabotegravir and rilpivirine [see Microbiology ( 12.4 )] .

Clinical Studies ( 14.1 )] . CABENUVA

a 2-drug co-packaged product of cabotegravir

an HIV-1 integrase strand transfer inhibitor (INSTI)

and rilpivirine

an HIV-1 non‑nucleoside reverse transcriptase inhibitor (NNRTI)

Contraindications

5 WARNINGS AND PRECAUTIONS • Serious or severe hypersensitivity reactions have been reported with cabotegravir- and rilpivirine-containing regimens
1 ) • Serious post-injection reactions with rilpivirine were reported
1 Hypersensitivity Reactions Serious or severe hypersensitivity reactions have been reported with cabotegravir- and rilpivirine-containing regimens
Administration of cabotegravir and rilpivirine oral lead-in dosing was used in clinical studies to help identify patients who may be at risk of a hypersensitivity reaction [see Dosage and Administration ( 2

3 documented side effects by frequency

Injection Site Pain

>10%

Fever

0.1-1%

Fatigue

0.1-1%

No community discussions found for CABOTEGRAVIR AND RILPIVIRINE yet.

0 available comparisons

No comparisons yet.

Dosage Forms

Tablet

Route

Oral